GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Humedix Co Ltd (XKRX:200670) » Definitions » EBIT

Humedix Co (XKRX:200670) EBIT : ₩48,411 Mil (TTM As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Humedix Co EBIT?

Humedix Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was ₩15,455 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was ₩48,411 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Humedix Co's annualized ROC % for the quarter that ended in Dec. 2024 was 26.77%. Humedix Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 73.95%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Humedix Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 19.02%.


Humedix Co EBIT Historical Data

The historical data trend for Humedix Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humedix Co EBIT Chart

Humedix Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20,565.86 13,573.57 32,154.05 33,856.35 48,410.88

Humedix Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,803.22 10,648.47 13,058.51 9,248.40 15,455.50

Competitive Comparison of Humedix Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Humedix Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Humedix Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Humedix Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Humedix Co's EV-to-EBIT falls into.


;
;

Humedix Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩48,411 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Humedix Co  (XKRX:200670) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Humedix Co's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=40743.784 * ( 1 - 17.77% )/( (125220.745 + 125092.887)/ 2 )
=33503.6135832/125156.816
=26.77 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=236107.039 - 14934.515 - ( 95951.779 - max(0, 17590.918 - 148070.868+95951.779))
=125220.745

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=249751.927 - 14335.148 - ( 110323.892 - max(0, 19354.035 - 160032.415+110323.892))
=125092.887

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Humedix Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=61821.992/( ( (51251.902 + max(34552.051, 0)) + (51813.378 + max(29583.814, 0)) )/ 2 )
=61821.992/( ( 85803.953 + 81397.192 )/ 2 )
=61821.992/83600.5725
=73.95 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(19975.233 + 30358.474 + 883.54199999999) - (14934.515 + 0 + 1730.683)
=34552.051

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(20484.281 + 26385.841 + 415.63999999998) - (14335.148 + 0 + 3366.8)
=29583.814

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Humedix Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=48410.876/254469.137
=19.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Humedix Co EBIT Related Terms

Thank you for viewing the detailed overview of Humedix Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Humedix Co Business Description

Traded in Other Exchanges
N/A
Address
268 Anyang Dongan Game Metallurgy, 502 Gwanyang-dong Anyang Mega Valley, Anyang, Gyeonggi, KOR, 431-809
Humedix Co Ltd is a cosmeceutical healthcare company. It supplies Hyaluronic Acid raw material medicine of low molecule and the high molecule which are used in arthritis medicine, eyedrops and in injections for ophthalmology. Further, it is dedicated to the development of new functional materials with diverse physiological activities including vitamin derivatives and supplies a variety of functional materials. In addition, it offers various medical devices, cosmetic and health functional foods. The business activities are primarily carried out through South Korea.

Humedix Co Headlines

No Headlines